SureTrader Nadex Advertisement SureTrader
Home > Boards > US Listed > Mining/Resources >

India Globalization Capital Inc (IGC)

Add IGC Price Alert      Hide Sticky   Hide Intro
Moderator: NetworkNewsWire
Search This Board: 
Last Post: 4/26/2017 2:29:30 PM - Followers: 94 - Board type: Free - Posts Today: 1

India Globalization Capital, Inc. (NYSE MKT: IGC) is a first mover in developing a portfolio of products using cannabis-based "combination therapies" for the treatment of pain and other conditions.

IGC's strategy is exciting and unique in that it is aiming to become a leader in the phytocannabinoid-based combination therapy specialty pharmaceutical sector. This first-mover advantage can potentially be formidable as it begins clinical trials and further builds its patent portfolio

IGC recently exited its legacy businesses and currently holds international investments in land and in a hotel project.


Investment Highlights

  • Building a patented portfolio of phytocannabinoid-based pharmaceutical and nutraceutical products for one of the world's fastest growing industries
    Positioning for first-mover advantage by developing novel therapies, applying for patents, and acquiring technologies from related industries
    Strategic alliance with International Pharma Trials provides expertise in the FDA process and pharma-trials


Development Pipeline

Through cutting-edge research, IGC is developing a product portfolio of phytocannabinoid-based therapies for the treatment of a wide range of life altering or life threatening indications, including neuropathic and cancer pain, epilepsy, end of life supportive care, adjunctive supportive therapies of chronic neurological and oncological diagnosis.

Target Markets

Attitudes toward cannabis have transformed substantially across the United States. Support for cannabis legalization is rapidly outpacing opposition; 53 percent of Americans believe cannabis should be made legal, compared with 44 percent supporting illegality of cannabis. Within this burgeoning market, IGC has identified key areas to which it can apply its phytocannabinoid-based therapies to address unmet medical needs.



The treatment of pain is a great challenge for health care professionals as it can often debilitate individuals in ways that affect their day-to-day functioning, which significantly impacts the nation's productivity and economy. The national cost of health care due to pain ranges from $560 billion to $635 billion. In addition, the health care cost attributed to the abuse of prescription opioids, closely related to pain, is approximately $25 billion.

A major disadvantage of using currently available drug therapies to treat chronic severe pain is that these opioid based drugs may lead to side effects like hallucinations, constipation, sedation, nausea, respiratory depression, and dysphoria.


IGC has applied for a U.S patent based on a novel therapy, IGC-502 indicated for seizures, using cannabinoid extracts. The therapy is administered, using a variety of delivery technologies, for indications in mammals such as dogs and cats. The therapy may also be useful in humans.

IGC expects to conduct metabolic profiling and apply to the FDA for trials over the next few years.



Approximately 50 million people worldwide are affected by epilepsy (Sanders, 2003), a condition attributed to multiple factors. In dogs and cats, seizures are often caused by abnormal brain activity. They can be subtle or cause violent convulsions. Some seizures only occur once, but repeated seizures require treatment to prevent larger areas of the brain from becoming affected.


IGC has applied for a U.S patent based on a novel therapy, IGC-502 indicated for seizures, using cannabinoid extracts. The therapy is administered, using a variety of delivery technologies, for indications in mammals such as dogs and cats. The therapy may also be useful in humans.

IGC expects to conduct metabolic profiling and apply to the FDA for trials over the next few years.


Eating Disorders

Cachexia is a condition that accompanies severe illness such as cancer and results in the weakness and wasting away of the body. Approximately 1.3 million people in the United States are experiencing cachexia associated with cancer, multiple sclerosis, Parkinson's disease, HIV/AIDS, and other progressive illnesses. Notably, cancer-induced anorexia/cachexia is responsible for about 20% of all cancer deaths.

IGC-504 and IGC-506

Indicated for a variety of eating disorders, including cachexia, IGC-504 and IGC 506 are unique combination therapies that, if proven out by clinical trials, are expected to treat medical refractory epilepsy and eating disorders respectively, with lower side effects than conventional mono therapies. IGC-506 is being developed for both human and veterinary use.


Industry Partnerships

IGC has established a strategic alliance with International Pharma Trials, whose doctors and researchers have expertise in disorders of the central and peripheral nervous system as well as expertise in the FDA process and pharma-trials.

The company continues to seek information exchanges with medical cannabis dispensaries, research scientists, doctors, medical and business professionals, and biotech companies working in the cannabinoid space.

Leveraging its business model and collaborative research, IGC can help commercialize products while finding innovative ways of helping patients benefit from cannabinoids.



Ram Mukunda, President, CEO and Director

Ram Mukunda has served as IGC's executive chairman, chief executive officer, and president since the company's inception on April 29, 2005. From January 1990 to May 2004, Mukunda served as founder, chairman, and chief executive officer of Startec Global Communications, an international telecommunications carrier focused on providing voice over Internet protocol (VOIP) services to emerging economies. Startec was the first pure play international long distance carrier. Mukunda was responsible for organizing, structuring and integrating a number of companies owned by Startec. Under Mukunda's tenure at Startec, the company made an IPO of its equity securities in 1997 on NASDAQ. Prior to Startec, Mr. Mukunda served as Strategic Planning Advisor at Intelsat, a communications satellite services provider.

Mukunda serves as an emeritus member on the Board of Visitors at the University of Maryland, School of Engineering. From 2001 to 2003, he was a council member at Harvard's Kennedy School of Government, Belfer Center of Science and International Affairs.

Mukunda is the recipient of several awards including, the 2013 University of Maryland's International Alumnus of the Year award, the 2001 Distinguished Engineering Alumnus Award, the 1998 Ernst & Young, LLP's Entrepreneur of the Year Award. He holds a B.S. degree in Electrical Engineering, a B.S degree in Mathematics, and a M.S. in Engineering from the University of Maryland.

John Cherin, CFO, Treasurer, PAO

John Cherin is a retired senior executive with international experience in assisting young companies. He has provided insight to top management and Board of Directors on strategic analysis and improvement of operating procedures in financial reporting and operations. From 1966 to 1997, Cherin gained his experience as a senior partner at Arthur Andersen while managing practices aimed at businesses in the US and overseas. In addition he founded and managed Cherin Global Consulting in 1997-2005 and the Cherin Group LLC in 2004 to date. He also served as CFO for IGC in its formative stages for the purpose of raising capital to enable IGC's launch in the post startup phase.

Cherin is a retired CPA, a graduate of Northeastern University class of 1966 and in 1967 was the Silver Medal Recipient from the Massachusetts Society of CPAs.

Claudia Grimaldi, General Manager, Director of Cabaran Ultima

Claudia Grimaldi is the general manager and director of IGC's project development and managing company in Malaysia. Grimaldi is responsible for coordinating the staff in various countries and ensuring timely and accurate regulatory compliance and statutory reporting. Prior to assuming her current role in 2013, she spent three years managing the office of the CEO.

Prior to IGC, Grimaldi worked in human resources and psychotherapy. She graduated Summa Cum Laude from Javeriana University, a top five University in Colombia, with a Bachelor of Arts in Psychology. She holds an MBA in General Management, graduating with Highest Honors, from Meredith College. Grimaldi is a member of Delta Mu Delta International Honor Society. She is also fluent in both English and Spanish.


India Globalization Capital
PO BOX 60642
Potomac, MD 20859-0642
Phone: (301) 983-0998

1324 Lexington Ave.
Suite 117
New York, NY 10128
Phone: (212) 418-1217


NetworkNewsWire is a moderator of this board. Please see disclaimer on the NetworkNewsWire website:

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
IGC News: Current Report Filing (8-k) 04/25/2017 08:31:44 AM
IGC News: Current Report Filing (8-k) 04/21/2017 05:30:46 PM
IGC News: Statement of Changes in Beneficial Ownership (4) 04/07/2017 08:24:37 AM
IGC News: Current Report Filing (8-k) 04/05/2017 06:03:24 AM
IGC News: Current Report Filing (8-k) 04/05/2017 06:03:24 AM
#5058   I see RAM A SCAM hired a promotion Sprycel 04/26/17 02:29:30 PM
#5057   I hope they didn't pay you a lot mondochello 04/25/17 03:26:30 PM
#5056   IGC Announces Engagement of NetworkNewsWire NetworkNewsWire 04/25/17 01:30:39 PM
#5055   IGC is a First Mover in Cannabinoid Combination Therapies NetworkNewsWire 04/24/17 02:09:30 PM
#5054   Wouldn't be surprised. You have a link for djmurdock 04/19/17 04:40:28 PM
#5053   Is no one aware the company is selling Sprycel 04/19/17 04:28:32 PM
#5052   No problem, looks like .30s are coming in quick. djmurdock 04/19/17 04:23:36 PM
#5051   Thanks for the correction! SteelHoss 04/19/17 03:44:00 PM
#5050   Mining companies turned into MJ companies give me djmurdock 04/18/17 09:16:37 PM
#5049   No prob. It really depends alot on the Striker77 04/18/17 09:03:59 PM
#5048   I hear ya on the OTC, there's rough djmurdock 04/18/17 09:01:37 PM
#5047   Thanks, I agree. Looks interesting and I like djmurdock 04/18/17 08:55:08 PM
#5046   A lot of the buy trades are very SteelHoss 04/18/17 07:48:56 PM
#5045   Ive held it for a few weeks and Striker77 04/18/17 07:22:32 PM
#5044   Looking for a good entry point on this djmurdock 04/18/17 01:17:17 PM
#5043   IGC Plans to Develop Cannabinoid Extract Therapies for NetworkNewsWire 04/13/17 03:29:44 PM
#5042   IGC Submits International Patent Applications for IGC-501 NetworkNewsWire 04/10/17 10:06:03 AM
#5041   IGC at the Forefront of Innovation Thanks to NetworkNewsWire 04/07/17 09:23:23 AM
#5040   OTC market you gotta be careful sup105 04/05/17 01:17:05 PM
#5039   I'm new to trading so learning as fast fsantes 04/05/17 11:06:52 AM
#5038   IGC Announces Sale of Brilliant Hallmark Stake NetworkNewsWire 04/05/17 10:18:17 AM
#5037   Usually one listed on NYSE rise till dollar sup105 04/05/17 12:35:57 AM
#5036   Triple by month end quad triple with news devilskyvin 04/04/17 08:51:43 PM
#5035   Still believe this will continue to rise? fsantes 04/04/17 05:17:33 PM
#5034   This will fly high !!! sup105 04/04/17 01:21:17 PM
#5033   Nice ~ I see that' I was watching ddbl_our_buck 04/04/17 10:35:18 AM
#5032   2 Mio shares in less than 2h. kukadu 04/04/17 10:26:26 AM
#5031   IGC From Mining to Marijuana NetworkNewsWire 03/31/17 03:29:34 PM
#5030   Pain-Reducing Combination Therapies Proving Successful thanks to Innovative, NetworkNewsWire 03/30/17 08:43:26 AM
#5029   IGC Aims to Become a Leading Provider of NetworkNewsWire 03/28/17 12:15:50 PM
#5028   IGC CEO Featured in Audio Interview with NetworkNewsWire NetworkNewsWire 03/23/17 09:40:08 AM
#5027   IGC Pioneering New Phytocannabinoid Products NetworkNewsWire 03/21/17 03:08:38 PM
#5026   IGC Files Provisional Patent for Treatment of Eating NetworkNewsWire 03/21/17 10:12:28 AM
#5025   Current Development Pipeline NetworkNewsWire 03/20/17 01:21:49 PM
#5024   Leadership Team NetworkNewsWire 03/20/17 01:20:15 PM
#5023   I've never see a stock with such small strykerdude 03/16/17 06:58:34 PM
#5022   IGC closing in on 3 month high Plenty of cataloop 03/16/17 12:45:21 PM
#5021   IGC medical marijuana people taking notice cataloop 03/16/17 11:53:39 AM
#5020   Unique Cannabis-Pharma Companies Trailblazing the Medical Cannabis Industry NetworkNewsWire 03/16/17 08:43:03 AM
#5019   This looks like it could potentially be a MCMarketShare 03/15/17 09:55:55 AM
#5018   IGC is “One to Watch” NetworkNewsWire 03/14/17 10:44:21 AM
#5017   Chart says bounce from here (chart) sweet crude 03/02/17 12:57:30 PM
#5016   Looks like folks are starting to take notice Lone Wolf 03/01/17 09:39:38 AM
#5015   Sweet!! Just left my terminal for dinner Lone Wolf 02/28/17 07:58:05 PM
#5014   8K out: IGC retires 2.4 million shars sweet crude 02/28/17 07:46:57 PM
#5013   Agree. There's been some nice accumulation the Lone Wolf 02/28/17 09:21:52 AM
#5012   Nice DD...This should erupt soon...NYSE WEED !!!! zino 02/28/17 09:13:13 AM
#5011   Just connecting a couple dots: $IGC Lone Wolf 02/28/17 07:53:18 AM
#5010   IGC medical pot and NYSE listed. cataloop 02/27/17 01:15:15 PM
#5009   Chart ready for rally back into .40's sweet crude 02/27/17 10:19:54 AM